Subscribe free

Cytoreductive Surgery & Peritoneum ·

Neoadjuvant Chemo Fails to Improve Outcomes in Colorectal Metastases

Neoadjuvant chemotherapy before CRS/HIPEC for metachronous colorectal peritoneal metastases offers no survival benefit and increases complication risks.

  • Patients receiving neoadjuvant chemotherapy had a complication rate of 25% versus 12.7% for those undergoing upfront surgery.
  • Length of hospital stay increased to 12 days with neoadjuvant treatment compared to 10 days without.

Surgeons should weigh these risks against potential benefits when considering neoadjuvant therapy in these patients.

Journal Article by Wach MM, Bank H (…) Ongchin M et 9 al. in Ann Surg Oncol

© 2026. Society of Surgical Oncology.

read the whole article in Ann Surg Oncol

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Cytoreductive Surgery & Peritoneum.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in Cytoreductive Surgery & Peritoneum

The latest stitches

Ann Surg Oncol28 Aug 2026

Prophylactic HIPEC Improves Survival in Advanced Colorectal Cancer

Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) significantly enhances peritoneal metastasis-free survival and disease-free survival in patients with locally advanced colorectal cancer, though overall survival rates and complication rates remain unchanged.

All papers in Cytoreductive Surgery & Peritoneum →